A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines
A Phase IIb Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in Antiretroviral-Naive HIV-1 Infected Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina
-
Rosario, Argentina
-
-
-
-
-
Wien, Austria
-
-
-
-
-
Campinas, Brazil
-
Curitiba, Brazil
-
Pinheiros, Brazil
-
Rio De Janeiro, Brazil
-
Sao Paulo, Brazil
-
-
-
-
-
Beijing, China
-
-
-
-
-
Paris, France
-
Paris Cedex 10, France
-
Paris Cedex 12, France
-
Tourcoing, France
-
-
-
-
-
Berlin, Germany
-
Freiburg, Germany
-
Köln, Germany
-
München, Germany
-
-
-
-
-
Ciudad De Mexico, Mexico
-
-
-
-
-
San Juan, Puerto Rico
-
-
-
-
-
Kazan, Russian Federation
-
Moscow, Russian Federation
-
Moscow N/A, Russian Federation
-
Nizhny Novgorod, Russian Federation
-
Saint-Petersburg, Russian Federation
-
St Petersburg, Russian Federation
-
Volgograd, Russian Federation
-
-
-
-
-
Bloemfontein, South Africa
-
Cape Town, South Africa
-
Johannesburg, South Africa
-
-
-
-
-
Bangkok, Thailand
-
Chiang Mai, Thailand
-
Khon Kaen, Thailand
-
-
-
-
-
Kampala, Uganda
-
-
-
-
-
London, United Kingdom
-
Manchester, United Kingdom
-
-
-
-
California
-
Beverly Hills, California, United States
-
-
District of Columbia
-
Washington, District of Columbia, United States
-
-
Florida
-
Orlando, Florida, United States
-
Tampa, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
-
New York
-
Stony Brook, New York, United States
-
-
North Carolina
-
Winston-Salem, North Carolina, United States
-
-
Texas
-
Addison, Texas, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented human immunodeficiency virus type 1 (HIV-1) infection
- Never been treated with an antiretroviral (ARV) treatment or therapeutic HIV vaccine, or received less than or equal to 2 weeks treatment prior to screening with an nucleoside reverse transcriptase inhibitors
- HIV-1 plasma viral load above 5000 HIV-1 RNA copies per milliliter, at screening
- Cortisol of at least 550 nano moles per liter (19.9 microgram per deciliter) at screening
- Sensitivity to investigator selected nucleosides, at screening
Exclusion Criteria:
- Currently having active Acquired Immunodeficiency Syndrome (AIDS) defining illness
- Known or suspected acute (primary) HIV-1 infection
- Any current or history of adrenal disorder, and an acute hepatitis A, B, or C infection
- Documented genotypic evidence of Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) resistance at screening
- Pregnant or breastfeeding females
- Not agree to protocol-defined effective use of contraception
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TMC278 25 mg
Participants will receive TMC278 25 mg once daily up to Week 96.
Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
|
TMC278 25 mg tablet will be administered once daily.
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Other Names:
|
|
Experimental: TMC278 75 mg
Participants will receive TMC278 75 mg once daily up to Week 144.
Later on, participants will receive TMC278 25 mg once daily up to Week 240.
|
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Other Names:
TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
|
|
Experimental: TMC278 150 mg
Participants will receive TMC278 150 mg once daily up to Week 96.
Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
|
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Other Names:
TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
|
|
Active Comparator: Efavirenz
Participants will receive efavirenz 600 mg once daily up to Week 96.
Later on, participants will have an option to continue on efavirenz until Week 144 or until Week 240.
|
Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Other Names:
Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Virologic Response at Week 48 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Time Frame: Week 48
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 48
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Virologic Response at Week 96 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Time Frame: Week 96
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 96
|
|
Number of Participants With Virologic Response at Week 96 (Viral Load Less Than 50 Copies Per mL) - Snapshot Analysis
Time Frame: Week 96
|
The analysis is based on the last observed viral load data within the Week 96 window.
Virologic response is defined as a viral load less than 50 copies/mL.
Missing viral load was considered as non-response.
|
Week 96
|
|
Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Time Frame: Week 240
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 240
|
|
Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 50 Copies Per mL) - Snapshot Analysis
Time Frame: Week 240
|
The analysis is based on the last observed viral load data within the Week 240 window.
Virologic response is defined as a viral load less than 50 copies/mL.
Missing viral load was considered as non-response.
|
Week 240
|
|
Number of Participants With Virologic Response at Week 240 (Viral Load Less Than 400 Copies/mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm
Time Frame: Week 240
|
The TLOVR algorithm was used to derive response, ie, response and loss of response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders.
Participants with intermittent missing viral load values were considered responders if the preceeding and succeeding visits indicated response.
In all other cases, intermittent values were imputed with nonresponse.
Resuppression after confirmed virologic failure was considered as failure in this algorithm.
|
Week 240
|
|
Change From Baseline in CD4+ Cell Count (Absolute) at Week 96
Time Frame: Baseline (Day 1 of Week 0) to Week 96
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of Week 0) to Week 96
|
|
Change From Baseline in CD4+ Cell Count (Relative) at Week 96
Time Frame: Baseline (Day 1 of Week 0) to Week 96
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of Week 0) to Week 96
|
|
Change From Baseline in CD4+ Cell Count (Absolute) at Week 240
Time Frame: Baseline (Day 1 of Week 0) to Week 240
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of Week 0) to Week 240
|
|
Change From Baseline in CD4+ Cell Count (Relative) at Week 240
Time Frame: Baseline (Day 1 of week 0) to Week 240
|
Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e.
change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.
|
Baseline (Day 1 of week 0) to Week 240
|
|
Number of Participants With Virologic Failure for the Resistance Determinations by Developing Mutations: First Available On-Treatment Genotypic Data After Failure
Time Frame: Week 240
|
Virologic failure for the resistance determinations was defined as a viral load greater than 0.5 log10 copies /mL above the nadir with a minimum of 500 copies/mL.
For this study, treatment-emergent mutations (for at least one treatment) are presented as Resistance associated mutation (RAMs): i) Non-nucleotide reverse transcriptase inhibitor (NNRTI) RAMs, ii) Nucleoside/tide reverse transcriptase inhibitor (N[t]RTI RAMs).
|
Week 240
|
|
Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours (AUC24h) for TMC278
Time Frame: Up to Week 96
|
For each participant, a single value for area under the plasma concentration-time curve from time of administration up to 24 hours post dosing (AUC24h) of TMC278 was estimated from a population pharmacokinetic model, based on all samples collected throughout the trial up to Week 96.
|
Up to Week 96
|
|
Trough Plasma Concentration (Ctrough) for TMC278
Time Frame: Up to Week 96
|
For each participant, a single value for trough (i.e.
predose) plasma concentration (Ctrough) of TMC278 was estimated from a population pharmacokinetic model, based on samples collected throughout the trial up to Week 96.
|
Up to Week 96
|
|
Number of Participants With Virologic Response (Viral Load Less Than 50 Copies Per mL) - as Defined by the Time to Loss of Virologic Response (TLOVR) Algorithm, by Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours (AUC24h) Quartiles
Time Frame: Up to Week 96
|
Quartile 1, 2, 3 and 4 of AUC24h means the quartile with the lowest 25%, 26-50%, 51-75% and the highest 25% of AUC24h values, respectively, irrespective of the different doses of TMC278.
For each participant, a single value for area under the plasma concentration-time curve from time of administration up to 24 hours post dosing (AUC24h) of TMC278 was estimated from a population pharmacokinetic model, based on all samples collected throughout the trial up to Week 96.
Virologic response was calculated by time to loss of virologic response (TLOVR) algorithm.
|
Up to Week 96
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Reverse Transcriptase Inhibitors
- Efavirenz
- Rilpivirine
Other Study ID Numbers
Other Study ID Numbers
- CR006760
- TMC278-C204 (Other Identifier: Tibotec Pharmaceuticals, Ireland)
- R278474-C204 (Other Identifier: Tibotec Pharmaceuticals, Ireland)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.